Featured Post from ChristianaCare

ChristianaCare and The Wistar Institute advance partnership with new cancer research strategies

Mar 16, 2022

4 min

ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is advancing its historic partnership with the Ellen and Ronald Caplan Cancer Center of The Wistar Institute in Philadelphia with three new research projects under way.


The new research projects consist of a population health study targeting triple negative breast cancer. Other projects focus on a new therapeutic target for epithelial ovarian cancer, the most lethal gynecologic cancer in the developed world, and the development of “mini organs” derived from stem cells.


Targeting triple negative breast cancer

Delaware has one of the highest incidence rates of triple-negative breast cancer in the United States. This highly aggressive cancer has few treatment options, because the cells test negative for three known treatment targets – estrogen, progesterone and HER2 protein receptors.


Working with patient data from the Graham Cancer Center, researchers are investigating potential contributing factors such as diet, alcohol use and genetic variants among women, and the effects of these on cancer metabolism. The team will also examine spatial relationships between cancer “hot spots”—geographic areas with a higher-than-expected prevalence—and modifiable risk factors.


Key resources for the study are blood and tissue samples from the Graham Cancer Center’s Tissue Procurement Center and its statewide High-Risk Family Cancer Registry.


The research team will be led by Director of Population Health Research at ChristianaCare Scott Siegel, Ph.D., and Lead Research Scientist Jennifer Sims Mourtada, Ph.D., at the Graham Cancer Center’s Cawley Center for Translational Cancer Research (CTCR). They will join Zachary Schug, Ph.D., at Wistar’s Molecular and Cellular Oncogenesis Program.


Researching novel therapy for ovarian cancer

The latest study supported by the Graham Cancer Center’s Tissue Procurement Program targets KAT6A expression as a novel therapy for ovarian cancer caused by a specific genetic mutation, called PP2R1A.


Epithelial ovarian cancer is the most common form of ovarian cancer and the leading cause of gynecologic cancer deaths in the United States. Chemoresistance to currently available platinum-based drugs like cisplatin represents a major treatment challenge, as more than 50 percent of affected women ultimately relapse and die from this disease.


Wistar’s Rugang Zhang, Ph.D., leader of the Immunology, Microenvironment and Metastases Program, is focused on developing novel therapeutics for subtypes of ovarian cancer that currently have no effective therapies and on improving the current standard of care. Dr. Zhang’s previous work suggests that KAT6A signaling plays a critical role in ovarian cancer progression. Targeting this signaling pathway could be an effective strategy for treating ovarian cancer.


Working with Dr. Zhang on this project are Graham Cancer Center gynecologic oncologists Mark Cadungog, M.D., director of Robotic Surgery, and Sudeshna Chatterjee-Paer, M.D., and Cawley CTCR’s Stephanie Jean, M.D., director of Gynecologic Oncology Research. Also collaborating with the team is Wistar’s Alessandro Gardini, Ph.D., assistant professor in the Gene Expression & Regulation Program.


‘Mini organs’ offer hope for therapeutics

Dr. Sims-Mourtada at the Cawley CTCR will lead a new program to culture organ-specific tissue from stem cells that could change the way diseases are studied and treated.


These so called “mini organs” or “organoids” are three-dimensional tissue cultures grown in the lab that replicate the complexity and functions of a specific tissue or organ found in the body. Organoids offer scientists a better model for how drugs and other therapeutics might interact with a patient’s particular type of tumor, opening new avenues for precision medicine.


“The ability to grow each patient’s tumor in a three-dimensional organoid along with our capability to create patient-derived xenograft or animal models as part of our PDX core, will allow us to fully capture the effects of genetic as well as gene altering behavioral and environmental influences that are lacking in current research models,” said Dr. Sims-Mourtada. “Our collaboration with Wistar to build these programs raises our clinical platform to the next level for studying new cancer biomarkers and treatments.”


Advancing a Pioneering Partnership

The Graham Cancer Center made history when it signed a first-of-its-kind agreement in 2011 with The Wistar Institute, pairing a National Cancer Institute, NCI-designated basic research institution with a community cancer center that is also an NCI Community Oncology Research Program (NCORP).


“Our partnership with Wistar has attracted national recognition as a model of collaboration that leverages cutting-edge research to benefit cancer prevention and therapy statewide,” says Nicholas J. Petrelli, M.D., Bank of America endowed medical director of ChristianaCare’s Helen F. Graham Cancer Center and Research Institute. “With Wistar, our productive collaborations over the last decade continue to drive discovery research toward clinical trials to benefit patients here at the Graham Cancer Center and in communities everywhere.”


“The Graham Center has been an ideal partner in our mission,” said Dario C. Altieri, M.D., Wistar president and CEO and director of the Ellen and Ronald Caplan Cancer Center. “Our scientists at Wistar have access to clinically-annotated primary patient specimens of the highest quality. As the majority of patients at the Graham Cancer Center are treatment naïve, this collaboration affords an opportunity to conduct unique, high impact mechanistic and correlative studies that will ultimately advance important scientific discoveries that hopefully will lead to better cancer therapies.”

Powered by

You might also like...

Check out some other posts from ChristianaCare

ChristianaCare Advances New Health Campus in Camden, Delaware to Close Care Gaps featured image

3 min

ChristianaCare Advances New Health Campus in Camden, Delaware to Close Care Gaps

ChristianaCare has taken another major step to expand access to high quality care across Delaware by submitting a Notice of Intent to the Delaware Health Resources Board to develop a new health campus in Camden. Like the Georgetown campus announced in February, the proposed campus will include a health center and a neighborhood hospital and is part of the $865 million statewide commitment announced last July. “For many people in central Delaware, getting timely emergency or specialty care can still mean long drives or long waits,” said Janice E. Nevin, M.D., MPH, president and CEO of ChristianaCare. “We are investing in facilities that bring care closer to where people live. This campus reflects our commitment to ensuring every Delawarean, no matter their ZIP code, can count on timely, compassionate, high-quality care close to home.” Closing Care Gaps in Central and Southern Delaware The approximately 38,000‑square‑foot Camden campus will be located on the west side of Route 13, just south of Lochmeath Way. It is expected to open in late 2028 or early 2029 and will bring primary care, specialty care and outpatient services together in one location, supported by eight emergency department beds and eight inpatient beds. The project will create 83 new jobs for the community, including 60 positions at the neighborhood hospital and 23 at the health center. Kent and Sussex counties are both designated as Medically Underserved Areas by the Health Resources and Services Administration. At the same time, the region is growing quickly. By 2030, the population in central and southern Delaware is expected to increase by 8 percent, with residents aged 65 and older growing even faster, by 22 percent. Shortages in primary care, behavioral health and specialty services have forced many residents to travel long distances for care. The Camden campus will help change that by bringing essential services closer to home. Expanding Capacity on a Strong Foundation The Camden campus represents a $58.1 million investment and reflects ChristianaCare’s focus on access, coordination and community need. ChristianaCare already provides a broad range of services in Kent County, including primary care, specialty care, behavioral health, rehabilitation, home health, hospice and virtual care. The Camden campus will build on this foundation by increasing capacity and making care more convenient as demand grows. Partnering to Deliver Care Close to Home ChristianaCare is partnering with Emerus Holdings, Inc. on the neighborhood hospital component. Emerus is the nation’s leading developer of this model, with 49 acute care facilities across the country. “Communities are stronger when people can depend on care close to home,” said Vic Schmerbeck, CEO of Emerus Holdings, Inc. “We are proud to partner with ChristianaCare to deliver a neighborhood hospital that provides high quality care in a setting designed around the needs of the community.” Growing Access Across the Region The ChristianaCare Georgetown campus is planned for 20769 DuPont Boulevard at an estimated cost of $65.1 million. ChristianaCare is also expanding this innovative care model beyond Delaware. In July 2025, the system opened a neighborhood hospital at its West Grove Campus in southern Chester County, Pennsylvania. Additional campuses are planned in Springfield and Aston in Delaware County, Pennsylvania.

ChristianaCare Forms Joint Venture For Cardiovascular Ambulatory Surgery Center featured image

4 min

ChristianaCare Forms Joint Venture For Cardiovascular Ambulatory Surgery Center

ChristianaCare, Cardiovascular Physicians of Delaware and its partner organization, US Health Partners, have formed a joint venture to establish a new cardiovascular ambulatory surgery center in Newark. This new facility will be launched through the ChristianaCare Atlas ASC partnership. This is a pivotal moment showcasing the power of a local health system, strength of a national ASC management company, and expert community-based physicians working together to deliver a lower cost, easy-to-access model of care to our community. “The ChristianaCare Cardiovascular Surgery Center at Newark represents a deep partnership between ChristianaCare and community cardiovascular experts who are truly committed to caring for this region,” said Kert F. Anzilotti, M.D., MBA, chief physician executive and president of The Medical Group at ChristianaCare. “By working side by side with trusted community physicians, we are aligning expertise and decision making to strengthen heart care across the region and ensure it continues to evolve with the needs of the people we serve.” “By expanding access to outpatient heart care, we can reduce wait times, improve the patient experience and lower the overall cost of care—while using our hospital resources more wisely and preserving capacity for patients who need complex or urgent cardiac services,” Anzilotti added. “With over 30 years of providing cardiac care to Delaware residents, we are proud to collaborate on this center,” said Brian Sarter, M.D., president of Cardiovascular Physicians of Delaware. For patients, this is about getting the right care, in the right place, at the right time. Patients will receive specialized heart care in a focused setting designed for same day procedures, with a smoother experience, faster recovery and seamless coordination with hospital care if it’s ever needed.” “This joint venture brings together ChristianaCare and Cardiovascular Physicians of Delaware’s strong clinical leadership and a proven outpatient care model,” said Aaron Snyder, M.D., chief executive officer of US Health Partners. “Our aim is to build and run a center that is efficient, reliable and patient-focused from day one, so physicians can focus on care and patients can count on a high-quality same-day experience close to home.” Reducing the Cost of Heart Care Ambulatory surgery centers lower the cost of heart care by safely moving appropriate procedures out of the hospital and into a more efficient outpatient setting. Most patients return home the same day, while hospitals preserve capacity for complex and urgent cases. As reported in Ambulatory Surgery Center News, outpatient procedures performed in ambulatory surgery centers cost 30 to 40 percent less than the same care delivered in hospitals, improving access and efficiency as demand for heart care continues to grow. The move also frees up limited hospital resources to better care for people with more complex or urgent cardiovascular needs. Meeting a Growing Need for Heart Care Heart disease remains the leading cause of death in Delaware, and demand for cardiovascular care is rising. According to the Delaware Population Consortium, the number of New Castle County residents age 65 and older is projected to increase by 23 percent by 2035, increasing pressure on cardiovascular services. Forecasts show outpatient heart and vascular procedures could reach nearly 10,800 annually for New Castle County residents by 2029 and more than 24,000 across the broader region, according to health care analytics firm Sg2. At the same time, hospital operating room capacity remains limited. Cardiovascular Physicians of Delaware’s many decades of experience in Newark and across the state positioned the group as a natural fit for the collaboration. Focused on Same Day Cardiovascular Care Expected to open in late 2027, the nearly 9,000 square foot center will be located on the second floor of the HealthCare Center at Christiana, across from Christiana Hospital. The center will focus exclusively on outpatient heart and vascular procedures. Services will include diagnostic heart catheterizations, coronary and peripheral vascular interventions, ablation procedures, pacemaker/ implantable defibrillator implantations and other minimally invasive cardiovascular procedures. Hospital based cardiac care will continue to be available for patients who need inpatient treatment, emergency care or more complex services. Other Details The project will cost an estimated $9.3 million and is expected to create 14 full time jobs across clinical, administrative, leadership and support roles. The facility represents an additional investment beyond ChristianaCare’s previously announced $865 million commitment to Delaware, reinforcing the organization’s focus on expanding services and improving health outcomes statewide. Key features of the surgery center include two new cardiac catheterization/ electrophysiology labs, dedicated pre operative and post anesthesia care space and on site sterile processing and administrative areas. Atlas Healthcare Partners will manage and operate the center, while Cardiovascular Physicians of Delaware will provide clinical oversight and perform outpatient surgical cases. ChristianaCare and Atlas Healthcare Partners formed the joint venture in 2024 to build an ambulatory surgery center network across the Mid-Atlantic region.

Union Hospital Earns Healthgrades 2026 Patient Safety Excellence Award for Second Consecutive Year featured image

1 min

Union Hospital Earns Healthgrades 2026 Patient Safety Excellence Award for Second Consecutive Year

Union Hospital has once again been ranked among the top 10% of hospitals nationwide, earning the 2026 Healthgrades Patient Safety Excellence Award™ for the second year in a row. In a landscape where many hospitals struggle to maintain consistency, Union Hospital is delivering a sustained streak of high reliability, driven by disciplined safety practices and a culture that puts patient protection first. Campus president Joan Pirrung captures it well: “Our caregivers are relentless about safety. Achieving this honor two years in a row shows the unwavering commitment they bring to every patient, every day.” At the heart of this repeat achievement is a team of caregivers who’ve built a culture where safety isn’t a program—it’s a daily practice. If you’re interested in the story behind these results, I can connect you with campus president Joan Pirrung for additional insight or interviews.

View all posts
Powered by